Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.
If you own shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) then it's worth thinking about how it contributes to...
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
Q4 2019 Intellia Therapeutics Inc Earnings Call
NTLA earnings call for the period ending March 31, 2020.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * AstraZeneca plc (NY…
CAMBRIDGE, Mass., Feb. 20, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeuti…
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the first quarter ended March 31, 2020. ATTR Program: Intellia’s lead candidate, NTLA-2001, is designed to apply its in vivo liver knockout approach for the treatment of transthyretin amyloidosis (ATTR) in a single course of treatment.
Joining me on today's call from Intellia are Dr. John Leonard, our Chief Executive Officer; Dr. Laura Sepp-Lorenzino, our Chief Scientific Officer; and Glenn Goddard, our Chief Financial Officer. Following their prepared remarks, we will be open for Q&A, for which Andrew Schiermeier, our Chief Operating Officer; and Jose Rivera, our General Counsel, will also be joining. Laura will provide an update on our R&D progress, and Glenn will review our financial results from the first quarter of 2020.
Intellia Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
Shares of Intellia Therapeutics (NASDAQ:NTLA) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were down 28.57% over the past year to ($0.63), which missed the estimate of ($0.44).Revenue of $12,916,000 higher by 23.80% year over year, which missed the estimate of $18,140,000.Guidance Earnings guidance hasn't been issued by the company for now.Intellia Therapeutics hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 07, 2020View more earnings on NTLATime: 09:05 AM ETWebcast URL: https://ir.intelliatx.com/events/event-details/intellia-therapeutics-first-quarter-2020-earnings-conference-callRecent Stock Performance 52-week high: $19.0052-week low: $9.18Price action over last quarter: Up 7.12%Company Description Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema and ex vivo programs targeting Wilms Tumor 1 for acute myeloid leukemia.See more from Benzinga * Malibu Boats: Q3 Earnings Insights * Heska: Q1 Earnings Insights * Recap: Agenus Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Intellia Therapeutics, Inc. (NTLA) has named David Lebwohl, M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience, and joins Intellia to lead its clinical development and regulatory organizations.
The analysts might have been a bit too bullish on Intellia Therapeutics, Inc. (NASDAQ:NTLA), given that the company...
引用元: http://tomcat.2ch.sc/test/read.cgi/livejupiter/1589294170/1: 風吹けば名無し 2020/05/12(火) 23:36:10.30 ID:sw5NSKP50 ガチなん？ 2: 風吹けば名無し 2020/05/12(火) 23:36:26.38 ID:euoiobFe0 ガチ 3: 風吹けば名無し 2020/05/12(火) 23:36:33.66 I...
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by its collaborator, Novartis, for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease (SCD). OTQ923 is a SCD treatment based on genome editing of hematopoietic stem cells (HSCs), using CRISPR/Cas9 RNA guides identified through Intellia’s cell therapy research collaboration with Novartis.
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas has more favorable terms for its collaborations with big pharma companies, but it still has a long way to go.
Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...
On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H...
CAMBRIDGE, Mass., April 30, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -5.56% and 14.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics (NASDAQ: NTLA) has appointed David Lebwohl to serve as executive vice president and chief medical officer. He is joining the Cambridge, MA-based gene-editing therapies company from Semma Therapeutics, where he also held the chief medi…
Our hosts look at some headwinds facing the restaurant industry and how they might survive the pandemic.
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting three oral presentations and two poster presentations at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually from May 12-15, 2020. Intellia researchers are presenting new data in support of NTLA-5001, the company’s engineered cell therapy candidate for the treatment of acute myeloid leukemia (AML). Intellia is also providing an update on NTLA-2002, its newest development candidate for the treatment of hereditary angioedema (HAE).
Operation Warp Speed: The COVID-19 vaccine race officially goes into high gear with the announcement of USA’s plan to test the 6-odd top vaccine candidates... The post Trumpdesivir: Operation Warp Speed, “Engage.” appeared first on ValueWalk.
CAMBRIDGE, Mass., April 28, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.